News

Stifel expects S&P 500 to peak in early 2025 before falling

The brokerage expects the U.S. stocks benchmark to drop to mid-5,000s late next year, a bearish view on the market when compared to Goldman Sachs and Morgan Stanley, which see the index end 2025 at 6,500. A correction in stocks could be triggered by the U.S. real gross domestic product slowing to 1.5% in the second half of 2025 and core personal consumption expenditure inflation staying above the Federal Reserve's target, Stifel strategists noted. The S&P 500 has had a strong run this year, rising about 27% so far, boosted by the so-called 'Magnificent 7' stocks rising on the artificial intelligence boom and anticipation of lower interest rates.

Buyout Firms Lead $25 Billion of Stock Sales on European Bourses

(Bloomberg) -- Buyout groups have been sitting on holdings built up as markets slumped after the pandemic. Now they’re helping fuel a bounce in Europe’s capital markets as they look to offload the backlog.Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxBrace for a Nationwide Shuffle of Corporate HeadquartersCity Hall Is HiringAmerican Institute of Architects CEO ResignsCloud Computing Tax Threatens Chicago’s Silicon Valley DreamInitial public offerings and selldowns

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

On Thursday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The CORAL trial is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) compared to placebo in IPF patients with